Pan Zhi Hua Shi

Researchers are evaluating the effectiveness and safety of a new eye drop called 0.1% STN1013800 ophthalmic solution in Chinese patients who have acquired blepharoptosis, a condition where the upper eyelid droops. This Phase III study addresses the lack of approved medications for this condition in China by comparing the investigational drug to a placebo. The trial aims to determine whether the treatment improves eyelid function and vision-related outcomes. Participants receive either the STN1013800 ophthalmic solution or a placebo liquid base without the active ingredient once daily for 42 days. Before starting treatment, there is a screening period lasting 3 to 7 days to confirm eligibility. The dosing and administration schedule follows previous clinical trial results, focusing on consistent daily application. During the study, participants undergo assessments including visual field tests and measurements of eyelid position at specific times on Day 1 and Day 14. Researchers monitor changes from baseline in these measures to evaluate treatment effects. Safety and adherence are observed throughout the 42-day treatment period to ensure participant well-being and reliable study results.

Researchers are evaluating the efficacy and safety of a combination budesonide and albuterol metered dose inhaler (MDI) compared with an albuterol sulfate MDI in symptomatic Chinese adults with asthma. This Phase III, randomized, double-blind, multicenter, event-driven study aims to reduce the risk of severe asthma exacerbations in this population. The study will enroll approximately 790 participants who meet specific asthma-related eligibility criteria. The study includes three periods: a screening period of 14 to 28 days, a treatment period lasting at least 24 weeks and up to 52 weeks, and a safety follow-up period occurring about two weeks after the final visit. Participants will be randomly assigned to one of two treatment groups, receiving either the budesonide/albuterol MDI or the albuterol sulfate MDI as needed for asthma symptoms or before exercise, alongside their usual maintenance therapy. Participants will undergo assessments including lung function tests, asthma control questionnaires, and monitoring of severe asthma exacerbations throughout the treatment period. Researchers will track the time to the first severe asthma exacerbation as the primary outcome. Safety will be monitored during the follow-up period, and participants must demonstrate the ability to use the inhaler correctly and comply with study procedures throughout the trial.

Researchers are evaluating the effects and safety of the drug TNTL in adults with non-proliferative diabetic retinopathy, a condition affecting the eyes related to diabetes. This Phase III clinical trial compares TNTL to a placebo to determine if TNTL can improve visual clarity and reduce the severity of retinopathy. The study also aims to identify any medical issues participants may experience while taking TNTL. Participants will take either TNTL or a placebo orally, four tablets three times a day after meals, for 24 weeks (6 months). They will visit the clinic every 4 weeks for checkups and testing during the treatment period. The study includes two groups: one receiving TNTL and the other receiving a placebo designed to look like TNTL. During the study, participants will keep a diary of symptoms and changes. Researchers will measure the change in best corrected visual acuity (BCVA) from the start of the study to the end of treatment at 24 weeks. Regular assessments and safety monitoring will be conducted throughout the 6-month treatment period to evaluate both effectiveness and safety.

This registry study is designed to monitor the safety and effectiveness of Medtronic Neurovascular products used in treating intracranial aneurysms and acute ischemic stroke. It is an observational, prospective, multi-center, single-arm study aiming to provide ongoing evaluation and periodic reports of these market-released devices. The study includes patients treated with specific Medtronic products under the Product Surveillance Registry platform. Participants will receive treatments involving the embolization of aneurysms or revascularization of intracranial blood vessels using Medtronic devices. The study collects data on patients who are treated or intended to be treated with these eligible products. Enrollment occurs within the treatment window, and patients may be followed according to the registry's protocol to gather safety and effectiveness information. During the study, participants will undergo assessments to measure the clinical success of treatment, defined as complete occlusion of the target aneurysm without retreatment or significant artery narrowing at one year, as well as functional independence measured by a modified Rankin Scale score at 90 days. Safety monitoring and follow-up are conducted to ensure long-term observation of outcomes. The study includes adult patients, and participation duration depends on follow-up schedules for the treated condition.

Researchers are evaluating the safety and effectiveness of atorvastatin in adults aged 18 to 80 years who have experienced spontaneous intracerebral hemorrhage (ICH). This multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study plans to enroll 264 patients who arrive within 3 to 24 hours after symptom onset. The goal is to see if atorvastatin can improve recovery compared to standard medical treatment alone. Participants will be randomly assigned to one of two groups: one group will receive best medical treatment according to current ICH guidelines, and the other will receive the same treatment plus atorvastatin at a dose of 20 mg once daily for 21 days. Treatment is started within 48 hours of symptom onset or last known well time. The study focuses on patients with hematomas in the supratentorial brain region, with specific volume and coma scale criteria. During the study, participants will be monitored for functional outcomes, with the primary measure being the proportion of patients who have poor functional recovery at about 90 days, defined by a modified Rankin Scale score of 4 to 6. The study includes assessments through imaging to confirm diagnosis and careful tracking of symptoms and clinical status throughout the treatment and follow-up periods to evaluate safety and efficacy.